Plan sponsors are able to dispute a PBM’s plan if it’s not reasonable or relevant, directly through CMS. Should PBMs refuse to provide 100% pass-through, the contract will no longer be reasonable.

A BTK inhibitor combined with standard R-CHOP produced rapid, PET-defined complete remission in high-risk DLBCL-type Richter syndrome with TP53 deletion. Delaying ibrutinib until cycle 2 was used as a ...

In an interview with the American Journal of Managed Care®, Greenspan explained why oxygen therapy is beneficial for patients ...

CMMI’s agenda centers on productivity and value-based payment expansion, including outcomes-based reimbursement, Most-Favored ...

GPT-4o achieved ICC/CCC of 0.815/0.866 versus in-person SALT scoring and 0.833/0.817 versus image-based scoring, while expert ...

Rebecca L. Siegel, MPH, lead author of the “Colorectal Cancer Statistics, 2026” report recently published in CA: A Cancer ...

Peter Staley at CROI 2026 on defending 45 years of HIV progress: how clinicians, payers, and advocates can resist—quietly or publicly—and why it matters.

Persistent underperformance of prior oncology VBC models reflects failure to measurably improve outcomes while lowering total ...

At the Winter Clinical Dermatology Meeting, April W. Armstrong, MD, MPH, professor and chief of dermatology at the UCLA ...

Extent of disease: Patients with 10% or less vitiligo and particularly facial or limited lesions tend to benefit most from ...

Fred D. Lublin, MD, discusses evolving concepts in MS, including earlier high-efficacy therapy, unrecognized progression, and ...

Clinicians must consider patient comorbidities and therapy safety when selecting immunotherapy for cSCC, says Todd ...